Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Nicotine Delivery Systems | 18 | 2024 | 194 | 7.370 |
Why?
|
| Tobacco Products | 18 | 2024 | 190 | 6.960 |
Why?
|
| Social Media | 9 | 2024 | 50 | 4.920 |
Why?
|
| Vaping | 11 | 2023 | 123 | 4.300 |
Why?
|
| Nicotine | 13 | 2024 | 82 | 3.440 |
Why?
|
| Substance-Related Disorders | 8 | 2024 | 166 | 3.160 |
Why?
|
| Sexual and Gender Minorities | 7 | 2024 | 36 | 3.150 |
Why?
|
| Cigarette Smoking | 5 | 2022 | 77 | 3.080 |
Why?
|
| Smoking Cessation | 9 | 2022 | 398 | 2.750 |
Why?
|
| Tobacco Use Disorder | 4 | 2022 | 115 | 1.940 |
Why?
|
| Adolescent | 20 | 2024 | 2957 | 1.900 |
Why?
|
| Smoking | 7 | 2022 | 465 | 1.650 |
Why?
|
| Intention | 4 | 2023 | 75 | 1.600 |
Why?
|
| Smokers | 5 | 2022 | 124 | 1.600 |
Why?
|
| Tobacco Use | 7 | 2024 | 83 | 1.570 |
Why?
|
| Young Adult | 16 | 2024 | 2581 | 1.550 |
Why?
|
| Humans | 52 | 2024 | 26829 | 1.510 |
Why?
|
| Male | 31 | 2024 | 12870 | 1.340 |
Why?
|
| Adult | 23 | 2024 | 7383 | 1.280 |
Why?
|
| Female | 31 | 2024 | 14463 | 1.260 |
Why?
|
| Cannabis | 2 | 2024 | 41 | 1.030 |
Why?
|
| Cross-Sectional Studies | 7 | 2024 | 910 | 0.900 |
Why?
|
| Lung Injury | 1 | 2023 | 31 | 0.860 |
Why?
|
| Cotinine | 2 | 2019 | 45 | 0.790 |
Why?
|
| Binge Drinking | 1 | 2021 | 6 | 0.740 |
Why?
|
| Health Equity | 1 | 2020 | 4 | 0.730 |
Why?
|
| Peer Group | 1 | 2021 | 36 | 0.730 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2021 | 40 | 0.720 |
Why?
|
| Health Status Disparities | 1 | 2020 | 60 | 0.690 |
Why?
|
| Health Behavior | 2 | 2020 | 154 | 0.670 |
Why?
|
| Biomedical Research | 1 | 2020 | 93 | 0.670 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 357 | 0.660 |
Why?
|
| Research Design | 1 | 2020 | 174 | 0.650 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 86 | 0.650 |
Why?
|
| Homosexuality, Female | 1 | 2019 | 3 | 0.650 |
Why?
|
| Bisexuality | 1 | 2019 | 3 | 0.650 |
Why?
|
| Homosexuality, Male | 1 | 2019 | 15 | 0.640 |
Why?
|
| Behavior, Addictive | 1 | 2019 | 23 | 0.640 |
Why?
|
| Prevalence | 4 | 2022 | 472 | 0.630 |
Why?
|
| Health Promotion | 1 | 2020 | 169 | 0.630 |
Why?
|
| Marijuana Use | 1 | 2018 | 32 | 0.600 |
Why?
|
| Social Networking | 1 | 2017 | 5 | 0.590 |
Why?
|
| Blood Donors | 1 | 2017 | 4 | 0.580 |
Why?
|
| Adolescent Behavior | 1 | 2018 | 67 | 0.570 |
Why?
|
| Pharmaceutical Preparations | 2 | 2023 | 44 | 0.570 |
Why?
|
| Interpersonal Relations | 1 | 2017 | 64 | 0.560 |
Why?
|
| Social Support | 1 | 2017 | 123 | 0.550 |
Why?
|
| Self Efficacy | 1 | 2017 | 72 | 0.540 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2016 | 10 | 0.540 |
Why?
|
| Outpatients | 1 | 2016 | 42 | 0.530 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 43 | 0.530 |
Why?
|
| Pharmacists | 1 | 2016 | 69 | 0.510 |
Why?
|
| Health Maintenance Organizations | 3 | 2011 | 9 | 0.490 |
Why?
|
| San Francisco | 3 | 2019 | 7 | 0.480 |
Why?
|
| Self Report | 3 | 2020 | 116 | 0.480 |
Why?
|
| Kidney | 1 | 2016 | 275 | 0.470 |
Why?
|
| Surveys and Questionnaires | 4 | 2022 | 918 | 0.460 |
Why?
|
| Tobacco | 3 | 2023 | 86 | 0.450 |
Why?
|
| Pandemics | 4 | 2021 | 166 | 0.420 |
Why?
|
| California | 3 | 2022 | 65 | 0.410 |
Why?
|
| Cities | 2 | 2021 | 14 | 0.370 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2011 | 14 | 0.360 |
Why?
|
| Job Satisfaction | 1 | 2011 | 24 | 0.360 |
Why?
|
| United States | 5 | 2024 | 2033 | 0.360 |
Why?
|
| Prospective Studies | 3 | 2024 | 1217 | 0.350 |
Why?
|
| Diazepam | 1 | 2010 | 3 | 0.350 |
Why?
|
| Anti-Anxiety Agents | 1 | 2010 | 7 | 0.350 |
Why?
|
| Primary Health Care | 1 | 2011 | 145 | 0.330 |
Why?
|
| Flavoring Agents | 4 | 2023 | 15 | 0.320 |
Why?
|
| Saliva | 2 | 2019 | 94 | 0.320 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2010 | 160 | 0.310 |
Why?
|
| Appetite Depressants | 2 | 2005 | 2 | 0.310 |
Why?
|
| Cyclobutanes | 2 | 2005 | 3 | 0.310 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 400 | 0.300 |
Why?
|
| Pilot Projects | 2 | 2020 | 390 | 0.290 |
Why?
|
| Menthol | 3 | 2023 | 18 | 0.290 |
Why?
|
| Sex Factors | 2 | 2018 | 446 | 0.280 |
Why?
|
| Cost-Benefit Analysis | 1 | 2005 | 108 | 0.240 |
Why?
|
| Weight Loss | 1 | 2005 | 72 | 0.240 |
Why?
|
| Cognitive Dissonance | 1 | 2024 | 1 | 0.230 |
Why?
|
| Hallucinogens | 1 | 2024 | 12 | 0.220 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2023 | 12 | 0.220 |
Why?
|
| Product Labeling | 1 | 2023 | 10 | 0.210 |
Why?
|
| Obesity | 3 | 2005 | 650 | 0.210 |
Why?
|
| Minority Groups | 2 | 2024 | 62 | 0.210 |
Why?
|
| Respiratory System | 1 | 2022 | 13 | 0.210 |
Why?
|
| Robotics | 1 | 2023 | 42 | 0.210 |
Why?
|
| Stress, Psychological | 1 | 2024 | 209 | 0.200 |
Why?
|
| Disease Susceptibility | 1 | 2022 | 72 | 0.200 |
Why?
|
| Social Behavior | 2 | 2020 | 52 | 0.200 |
Why?
|
| Tobacco, Smokeless | 1 | 2022 | 43 | 0.200 |
Why?
|
| Feasibility Studies | 1 | 2022 | 187 | 0.200 |
Why?
|
| Policy | 1 | 2021 | 11 | 0.190 |
Why?
|
| Odds Ratio | 1 | 2022 | 230 | 0.190 |
Why?
|
| Attitude | 1 | 2021 | 42 | 0.180 |
Why?
|
| Counseling | 1 | 2021 | 52 | 0.180 |
Why?
|
| Perception | 1 | 2021 | 81 | 0.180 |
Why?
|
| Search Engine | 1 | 2020 | 7 | 0.180 |
Why?
|
| Risk-Taking | 1 | 2021 | 57 | 0.180 |
Why?
|
| Aged | 4 | 2021 | 5167 | 0.180 |
Why?
|
| Taxes | 1 | 2020 | 12 | 0.180 |
Why?
|
| Anxiety | 1 | 2021 | 140 | 0.180 |
Why?
|
| Sleep Hygiene | 1 | 2020 | 1 | 0.170 |
Why?
|
| Los Angeles | 1 | 2020 | 13 | 0.170 |
Why?
|
| Cercopithecus | 1 | 2020 | 2 | 0.170 |
Why?
|
| Health Risk Behaviors | 1 | 2020 | 6 | 0.170 |
Why?
|
| Growth and Development | 1 | 2020 | 7 | 0.170 |
Why?
|
| Bradykinin | 1 | 2019 | 27 | 0.170 |
Why?
|
| Allostasis | 1 | 2020 | 5 | 0.170 |
Why?
|
| Commerce | 1 | 2020 | 47 | 0.170 |
Why?
|
| Alcoholism | 1 | 2021 | 116 | 0.170 |
Why?
|
| Veins | 1 | 2019 | 19 | 0.170 |
Why?
|
| Mobile Applications | 1 | 2020 | 58 | 0.170 |
Why?
|
| Afferent Pathways | 1 | 2019 | 62 | 0.170 |
Why?
|
| Colorado | 3 | 2011 | 47 | 0.170 |
Why?
|
| Pericardium | 1 | 2019 | 47 | 0.170 |
Why?
|
| Sympathetic Nervous System | 1 | 2019 | 64 | 0.170 |
Why?
|
| Depression | 1 | 2021 | 211 | 0.170 |
Why?
|
| Social Environment | 1 | 2020 | 56 | 0.170 |
Why?
|
| Cohort Studies | 1 | 2022 | 858 | 0.170 |
Why?
|
| Vasodilator Agents | 1 | 2019 | 79 | 0.170 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2019 | 77 | 0.160 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 980 | 0.160 |
Why?
|
| Sexuality | 1 | 2019 | 4 | 0.160 |
Why?
|
| Reflex | 1 | 2019 | 74 | 0.160 |
Why?
|
| Gender Identity | 1 | 2019 | 20 | 0.160 |
Why?
|
| Transgender Persons | 1 | 2019 | 9 | 0.160 |
Why?
|
| Hemodynamics | 1 | 2019 | 220 | 0.160 |
Why?
|
| Energy Metabolism | 1 | 2020 | 178 | 0.150 |
Why?
|
| Friends | 1 | 2018 | 12 | 0.150 |
Why?
|
| Placebo Effect | 1 | 2018 | 6 | 0.150 |
Why?
|
| Prognosis | 1 | 2020 | 759 | 0.150 |
Why?
|
| Persuasive Communication | 1 | 2018 | 13 | 0.150 |
Why?
|
| Diet | 1 | 2020 | 223 | 0.150 |
Why?
|
| Professional-Patient Relations | 1 | 2018 | 28 | 0.150 |
Why?
|
| Psychological Theory | 1 | 2018 | 29 | 0.150 |
Why?
|
| Family | 1 | 2018 | 98 | 0.140 |
Why?
|
| Models, Psychological | 1 | 2018 | 80 | 0.140 |
Why?
|
| Social Norms | 1 | 2017 | 11 | 0.140 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 445 | 0.140 |
Why?
|
| Mental Health | 3 | 2024 | 96 | 0.140 |
Why?
|
| Cues | 1 | 2017 | 38 | 0.140 |
Why?
|
| Drug Dosage Calculations | 1 | 2016 | 4 | 0.140 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 162 | 0.140 |
Why?
|
| Contraindications | 1 | 2016 | 13 | 0.140 |
Why?
|
| Motivation | 1 | 2018 | 207 | 0.130 |
Why?
|
| Exercise | 1 | 2021 | 451 | 0.130 |
Why?
|
| Age Factors | 1 | 2018 | 716 | 0.130 |
Why?
|
| Biomarkers | 1 | 2019 | 733 | 0.130 |
Why?
|
| Middle Aged | 4 | 2021 | 6818 | 0.130 |
Why?
|
| Child | 1 | 2021 | 2147 | 0.120 |
Why?
|
| Students | 1 | 2017 | 188 | 0.120 |
Why?
|
| Time Factors | 1 | 2018 | 1562 | 0.110 |
Why?
|
| Heterosexuality | 2 | 2024 | 17 | 0.100 |
Why?
|
| Organizational Culture | 1 | 2011 | 24 | 0.090 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 74 | 0.090 |
Why?
|
| Interprofessional Relations | 1 | 2011 | 63 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2011 | 112 | 0.080 |
Why?
|
| Cannabinoid Receptor Agonists | 1 | 2024 | 6 | 0.060 |
Why?
|
| Human Growth Hormone | 1 | 2004 | 14 | 0.060 |
Why?
|
| Marketing | 1 | 2024 | 34 | 0.060 |
Why?
|
| Metformin | 1 | 2004 | 32 | 0.060 |
Why?
|
| Disease Management | 1 | 2004 | 84 | 0.050 |
Why?
|
| Metabolic Syndrome | 1 | 2004 | 77 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2023 | 43 | 0.050 |
Why?
|
| Smoke | 1 | 2023 | 36 | 0.050 |
Why?
|
| Anxiety Disorders | 1 | 2023 | 59 | 0.050 |
Why?
|
| Blood Pressure | 2 | 2019 | 351 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2004 | 300 | 0.050 |
Why?
|
| Body Composition | 1 | 2004 | 260 | 0.050 |
Why?
|
| Logistic Models | 1 | 2022 | 397 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 43 | 0.040 |
Why?
|
| Oklahoma | 1 | 2024 | 973 | 0.040 |
Why?
|
| Cercopithecidae | 1 | 2020 | 1 | 0.040 |
Why?
|
| C-Peptide | 1 | 2020 | 8 | 0.040 |
Why?
|
| Grooming | 1 | 2020 | 3 | 0.040 |
Why?
|
| Receptors, Bradykinin | 1 | 2019 | 1 | 0.040 |
Why?
|
| Norepinephrine | 1 | 2019 | 32 | 0.040 |
Why?
|
| Competitive Behavior | 1 | 2020 | 17 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2019 | 34 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2020 | 114 | 0.040 |
Why?
|
| Behavior, Animal | 1 | 2020 | 107 | 0.040 |
Why?
|
| Feces | 1 | 2020 | 107 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2019 | 162 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2019 | 545 | 0.040 |
Why?
|
| Heart Rate | 1 | 2019 | 374 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2020 | 587 | 0.040 |
Why?
|
| Rats | 1 | 2019 | 1546 | 0.030 |
Why?
|
| Animals | 2 | 2020 | 9963 | 0.030 |
Why?
|
| Health Services Research | 1 | 2004 | 40 | 0.010 |
Why?
|
| Body Constitution | 1 | 2004 | 11 | 0.010 |
Why?
|
| Growth Hormone-Releasing Hormone | 1 | 2004 | 10 | 0.010 |
Why?
|
| Placebos | 1 | 2004 | 45 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 2004 | 57 | 0.010 |
Why?
|
| Arginine | 1 | 2004 | 39 | 0.010 |
Why?
|
| Fibrinogen | 1 | 2004 | 50 | 0.010 |
Why?
|
| Testosterone | 1 | 2004 | 70 | 0.010 |
Why?
|
| Body Weight | 1 | 2004 | 246 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2004 | 399 | 0.010 |
Why?
|
| Lipids | 1 | 2004 | 195 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2004 | 165 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2004 | 290 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2004 | 322 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2004 | 2264 | 0.010 |
Why?
|